Form 4: Artiva Executive Sells Shares for Tax Obligations

Chief Tech Operations Officer Christopher Horan sold 7,002 shares of Artiva Biotherapeutics to satisfy tax withholding requirements.

Summary

• Christopher Horan, Chief Tech Operations Officer, sold 7,002 shares of common stock on May 19, 2026.
• The shares were sold at a weighted average price of $9.0078, with individual transaction prices ranging from $8.7421 to $9.0104.
• The total value of the transaction was approximately $63,072.61.
• This sale was non-discretionary and conducted under a mandatory sell-to-cover policy to satisfy tax liabilities arising from the vesting of restricted stock units (RSUs).
• Following the sale, Christopher Horan remains the direct owner of 293,450 shares of the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it involves insider selling, the non-discretionary nature for tax purposes means it carries no negative signal regarding the company's fundamentals.

Positives

• The reporting person retains a substantial direct ownership of 293,450 shares, indicating continued alignment with shareholder interests.
• The sale was non-discretionary, meaning it does not reflect a lack of confidence in the company's future performance by the executive.

Negatives

• The sale represents a minor reduction in the executive's total equity position.

Risks

• No specific business or operational risks were disclosed in this transaction-focused filing.

Future Outlook

The filing does not provide specific forward-looking guidance, as it is a standard disclosure of a change in beneficial ownership.

Management Comments

• The Issuer has adopted a sell-to-cover policy to satisfy the tax withholding obligations of the Reporting Person.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

StockSavvy.ai notes that sell-to-cover transactions are a routine administrative occurrence in the biotech sector, where executives often receive a significant portion of their compensation in equity and must liquidate a portion to meet immediate tax burdens upon vesting.

Comparison to Industry Standards

• The use of a sell-to-cover policy is a standard corporate governance practice among NASDAQ-listed biotechnology firms like Artiva Biotherapeutics.
• The executive's retention of over 97% of his position following the tax-related sale is consistent with high-conviction insider behavior seen at peer clinical-stage companies.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as the sale volume is low relative to the executive's total holdings and the company's float.

Next Steps

• Monitoring of future Form 4 filings to track further RSU vestings and potential discretionary trading by insiders.

Key Dates

Recommendation

The filing represents a routine administrative transaction for tax purposes. There is no change in the company's strategic direction or executive sentiment that would warrant a change in investment thesis based solely on this document.

Keywords

Artiva Biotherapeutics, ARTV, Insider Trading, Form 4, Christopher Horan, Sell-to-Cover, Restricted Stock Units, Biotechnology, Executive Compensation